Company intelligence / Profile preview

Prothex

United States

Ownership: Private
Development stage: Other

Overview

Prothex is a clinical-stage pharmaceutical company focused on the development of RRx-001, a small molecule currently in Phase 2 clinical trials for prevention and reduction of severe oral mucositis in patients receiving chemoradiation for head and neck cancer. The Phase 2 trial (NCT03515538) demonstrated safety and explored efficacy endpoints regarding reduction of oral mucositis severity and duration in this patient population[6].

Therapeutic areas: OncologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

EpicentRx

Beyond the preview

Go deeper on Prothex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prothex.

Explore the full profile